Laden…
Synapedia is an independent knowledge project about psychoactive substances and harm reduction. If the platform helps you learn something new, you can support its development.
Every bit helps keep the project alive.
Substance Comparison
Benzodiazepine stands out with markedly stronger addiction risk. CBD leans slightly higher in psychedelic depth. Benzodiazepine leans slightly higher in sedation. CBD leans slightly higher in empathy & warmth.
Comparing these substances helps illustrate the diversity of psychoactive pharmacology and their distinct risk profiles.
Benzodiazepine has significantly higher addiction risk
CBD has somewhat higher psychedelic depth
Benzodiazepine has somewhat higher sedation
CBD has somewhat higher empathy & warmth
| Benzodiazepine | CBD | |
|---|---|---|
| Class | Depressiva | Cannabinoide |
| Risk Level | moderate | low |
| Mechanisms | Positive allosterische Modulation am GABA-A-Rezeptor | CB1-negativer allosterischer Modulator, 5-HT1A-Agonist |
| Receptors | GABA-A | CB1, 5-HT1A |
| Effects | — | Beeinflussung des Appetits, Müdigkeit, Durchfall, Schmerzlinderung, Reduktion von Angstzuständen |
| Evidence | — | moderate |
Cannabidiol (CBD) hat eine komplexe Pharmakologie mit mehreren Zielstrukturen. KRITISCH: CBD bindet NICHT signifikant an CB1- oder CB2-Endocannabinoid-Rezeptoren. Primäre Mechanismen: (1) 5-HT1A-Partialagonismus (anxiolytisch, antidepressiv), (2) TRPV1-Kanal-Agonismus (analgetisch, neuroprotektiv), (3) Negativer allosterischer Modulator am CB1-Rezeptor (dämpft THC-Effekte), (4) GPR55-Antagonismus (antiepileptisch), (5) Adenosin-Transporter-Inhibition (antiinflammatorisch), (6) FAAH-Inhibition (Erhöhung endogener Anandamid-Spiegel). CBD ist auch ein schwacher CYP2C19- und CYP3A4-Inhibitor mit klinischen Arzneimittelinteraktions-Implikationen.
Harm Reduction
No harm reduction data available
Safer-use data available on substance page
Evidence: not assessed · Sources: 2
Evidence: moderate · Sources: 5